Videos
Second-Line Therapy in Extranodal Marginal Zone Lymphoma
Perspective on Treating Advanced Marginal Zone Lymphoma
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Lung Cancer
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Atezolizumab Elicits Durable Responses in R/R Extranodal NK/T-Cell Lymphoma
2
Alert-Based ePRO Monitoring Reduces Fatigue in Metastatic Breast Cancer
3
Longitudinal Data Shapes Our Understanding of High-Risk Multiple Myeloma
4
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant Glioma
5